Overview

Effect of Empagliflozin on Body Composition and Ketones

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate changes of body composition induced by Sodium-glucose cotransporter-2 (SGLT2) inhibitor and its metabolic consequence in Korean type 2 diabetes (T2D).
Phase:
Phase 4
Details
Lead Sponsor:
Seoul National University Bundang Hospital
Treatments:
Empagliflozin
Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors